Intronic variation of the SOHLH2 gene confers risk to male reproductive impairment.


Journal

Fertility and sterility
ISSN: 1556-5653
Titre abrégé: Fertil Steril
Pays: United States
ID NLM: 0372772

Informations de publication

Date de publication:
08 2020
Historique:
received: 20 12 2019
revised: 06 02 2020
accepted: 28 02 2020
pubmed: 22 7 2020
medline: 20 4 2021
entrez: 22 7 2020
Statut: ppublish

Résumé

To evaluate whether SOHLH2 intronic variation contributes to the genetic predisposition to male infertility traits, including severe oligospermia (SO) and different nonobstructive azoospermia (NOA) clinical phenotypes. Genetic association study. Not applicable. Five hundred five cases (455 infertile patients diagnosed with NOA and 50 with SO) and 1,050 healthy controls from Spain and Portugal. None. Genomic DNA extraction from peripheral blood mononuclear cells, genotyping of the SOHLH2 polymorphisms rs1328626 and rs6563386 using the TaqMan allelic discrimination technology, case-control association analyses using logistic regression models, and exploration of functional annotations in publicly available databases. Evidence of association was observed for both rs6563386 with SO and rs1328626 with unsuccessful sperm retrieval after testicular sperm extraction (TESE-) in the context of NOA. A dominant effect of the minor alleles was suggested in both associations, either when the subset of patients with the manifestation were compared against the control group (rs6563386/SO: P=.021, odds ratio [OR] = 0.51; rs1328626/TESE-: P=.066, OR = 1.46) or against the group of patients without the manifestation (rs6563386/SO: P=.014, OR = 0.46; rs1328626/TESE-: P=.012, OR = 2.43). The haplotype tests suggested a combined effect of both polymorphisms. In silico analyses evidenced that this effect could be due to alteration of the isoform population. Our data suggest that intronic variation of SOHLH2 is associated with spermatogenic failure. The genetic effect is likely caused by different haplotypes of rs6563386 and rs1328626, which may predispose to SO or TESE- depending on the specific allelic combination.

Identifiants

pubmed: 32690270
pii: S0015-0282(20)30247-8
doi: 10.1016/j.fertnstert.2020.02.115
pii:
doi:

Substances chimiques

Basic Helix-Loop-Helix Transcription Factors 0
SOHLH2 protein, human 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

398-406

Investigateurs

Carlos Calhaz-Jorge (C)
Ana Aguiar (A)
Joaquim Nunes (J)
Sandra Sousa (S)
Maria Graça Pinto (M)
Sónia Correia (S)
Alberto Pacheco (A)
Cristina González (C)
Susana Gómez (S)
David Amorós (D)
Jesús Aguilar (J)
Fernando Quintana (F)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Auteurs

Miriam Cerván-Martín (M)

Departamento de Genética e Instituto de Biotecnología, Universidad de Granada, Granada, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.

M Irene Suazo-Sánchez (MI)

Departamento de Genética e Instituto de Biotecnología, Universidad de Granada, Granada, Spain.

Rocío Rivera-Egea (R)

Andrology Laboratory and Sperm Bank, IVIRMA Valencia, Valencia, Spain; IVI Foundation, Health Research Institute La Fe, Valencia, Spain.

Nicolás Garrido (N)

IVI Foundation, Health Research Institute La Fe, Valencia, Spain; Servicio de Urología. Hospital Universitari i Politecnic La Fe e Instituto de Investigación Sanitaria La Fe, Valencia, Spain.

Saturnino Luján (S)

Servicio de Urología. Hospital Universitari i Politecnic La Fe e Instituto de Investigación Sanitaria La Fe, Valencia, Spain.

Gema Romeu (G)

Servicio de Urología. Hospital Universitari i Politecnic La Fe e Instituto de Investigación Sanitaria La Fe, Valencia, Spain.

Samuel Santos-Ribeiro (S)

IVI-RMA Lisbon, Lisbon, Portugal; Department of Obstetrics and Gynecology, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.

José A Castilla (JA)

Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain; Unidad de Reproducción, UGC Obstetricia y Ginecología, HU Virgen de las Nieves, Granada, Spain; CEIFER Biobanco - NextClinics, Granada, Spain.

M Carmen Gonzalvo (MC)

Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain; Unidad de Reproducción, UGC Obstetricia y Ginecología, HU Virgen de las Nieves, Granada, Spain.

Ana Clavero (A)

Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain; Unidad de Reproducción, UGC Obstetricia y Ginecología, HU Virgen de las Nieves, Granada, Spain.

F Javier Vicente (FJ)

Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain; UGC de Urología, HU Virgen de las Nieves, Granada, Spain.

Vicente Maldonado (V)

UGC de Obstetricia y Ginecología, Complejo Hospitalario de Jaén, Jaén, Spain.

Miguel Burgos (M)

Departamento de Genética e Instituto de Biotecnología, Universidad de Granada, Granada, Spain.

Francisco J Barrionuevo (FJ)

Departamento de Genética e Instituto de Biotecnología, Universidad de Granada, Granada, Spain.

Rafael Jiménez (R)

Departamento de Genética e Instituto de Biotecnología, Universidad de Granada, Granada, Spain.

Josvany Sánchez-Curbelo (J)

Laboratory of Seminology and Embryology, Andrology Service-Fundació Puigvert, Barcelona, Spain.

Olga López-Rodrigo (O)

Laboratory of Seminology and Embryology, Andrology Service-Fundació Puigvert, Barcelona, Spain.

M Fernanda Peraza (MF)

Laboratory of Seminology and Embryology, Andrology Service-Fundació Puigvert, Barcelona, Spain.

Iris Pereira-Caetano (I)

Departamento de Genética Humana, Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal.

Patricia I Marques (PI)

Instituto de Investigação e Inovação em Saúde, Universidade do Porto (I3S), Porto, Portugal; Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal.

Filipa Carvalho (F)

Serviço de Genética, Departamento de Patologia, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.

Alberto Barros (A)

Serviço de Genética, Departamento de Patologia, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.

Lluís Bassas (L)

Laboratory of Seminology and Embryology, Andrology Service-Fundació Puigvert, Barcelona, Spain.

Susana Seixas (S)

Instituto de Investigação e Inovação em Saúde, Universidade do Porto (I3S), Porto, Portugal; Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal.

João Gonçalves (J)

Departamento de Genética Humana, Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal; ToxOmics - Centro de Toxicogenómica e Saúde Humana, Nova Medical School, Lisbon, Portugal.

Sara Larriba (S)

Human Molecular Genetics Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Alexandra M Lopes (AM)

Instituto de Investigação e Inovação em Saúde, Universidade do Porto (I3S), Porto, Portugal; Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal.

Rogelio J Palomino-Morales (RJ)

Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain; Departamento de Bioquímica y Biología Molecular I, Universidad de Granada, Granada, Spain. Electronic address: rpm@ugr.es.

F David Carmona (FD)

Departamento de Genética e Instituto de Biotecnología, Universidad de Granada, Granada, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH